Welcome to our dedicated page for RACA news (Ticker: RACA), a resource for investors and traders seeking the latest updates and insights on RACA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RACA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RACA's position in the market.
Therapeutics Acquisition Corp, trading as Research Alliance Corp. I (Nasdaq: RACA), announced the SEC's declaration of effectiveness for its Form S-4 registration statement related to its business combination with POINT Biopharma Inc. A definitive proxy statement/prospectus for a Special Meeting of stockholders on June 29, 2021, will be mailed to shareholders of record as of June 4, 2021. POINT Biopharma focuses on developing radiopharmaceuticals for cancer treatment, aiming to innovate drug development and commercialization.
POINT Biopharma has initiated dosing in its Phase 3 SPLASH study of PNT2002, a targeted radioligand therapy for patients with PSMA expressing metastatic castration-resistant prostate cancer (mCRPC) who are ineligible for chemotherapy. The study aims to enroll 450 patients across North America and Europe, comparing PNT2002 with standard treatments Abiraterone or Enzalutamide. Primary endpoint is radiographic progression-free survival. A merger with Research Alliance Corp. I (RACA) is also noted, with the combined company expected to be listed on Nasdaq as PNT.
POINT Biopharma has received a Materials License from the U.S. Nuclear Regulatory Commission for its new production facility in Indianapolis, Indiana. The facility, covering 80,000 square feet, will be one of the largest radiopharmaceutical manufacturing centers globally, focusing on precision radioligand therapy for cancer patients. This milestone allows POINT to utilize radioisotopes like Lutetium-177 and Actinium-225 for drug manufacturing, supporting its Phase 3 clinical trial for metastatic castration-resistant prostate cancer. POINT is merging with Research Alliance Corp. I (RACA), with expectations to list under the ticker symbol ‘PNT’.
